tiprankstipranks
Advertisement
Advertisement

APRE Stock Latest News

Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
Company AnnouncementsAprea Therapeutics Raises $30M to Advance Oncology Pipeline
9d ago
8K
APRE
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
10d ago
APRE
Aprea Therapeutics Announces $30 Million Private Placement
PremiumCompany Announcements
Aprea Therapeutics Announces $30 Million Private Placement
11d ago
8K
APRE
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
PremiumThe Fly
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
11d ago
APRE
Aprea Highlights Early APR-1051 Data and Financial Update
PremiumCompany Announcements
Aprea Highlights Early APR-1051 Data and Financial Update
25d ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
PremiumThe FlyAprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
25d ago
APRE
Aprea Therapeutics sees cash runway into 1Q27
Premium
The Fly
Aprea Therapeutics sees cash runway into 1Q27
25d ago
APRE
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
2M ago
APRE
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
PremiumRatings
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
2M ago
APRE
Aprea Highlights Encouraging Phase 1 Data for APR-1051
PremiumCompany Announcements
Aprea Highlights Encouraging Phase 1 Data for APR-1051
2M ago
8K
APRE
Aprea Therapeutics announces additional clinical activity for APR-1051
PremiumThe Fly
Aprea Therapeutics announces additional clinical activity for APR-1051
2M ago
APRE
Aprea announces expansions of its global intellectual property estate
PremiumThe Fly
Aprea announces expansions of its global intellectual property estate
2M ago
APRE
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
PremiumRatingsAPR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
2M ago
APRE
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
Premium
The Fly
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
2M ago
APRE
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
Premium
The Fly
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
2M ago
APRE
Aprea Therapeutics Announces Financing and Early Trial Response
PremiumCompany Announcements
Aprea Therapeutics Announces Financing and Early Trial Response
2M ago
8K
APRE
Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
2M ago
APRE
Aprea Therapeutics prices 6.29M shares at 89c in private placement
PremiumThe Fly
Aprea Therapeutics prices 6.29M shares at 89c in private placement
2M ago
APRE
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
PremiumThe Fly
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
2M ago
APRE
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
PremiumCompany AnnouncementsAprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
3M ago
8K
APRE
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
4M ago
APRE
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
Premium
Ratings
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
4M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >